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ANALYTIC PERSPECTIVE
Mitigation of biases in estimating hazard 
ratios under non-sensitive and non-specific 
observation of outcomes–applications 
to influenza vaccine effectiveness
Ulrike Baum1* , Sangita Kulathinal2 and Kari Auranen3,4
Abstract 
Background: Non-sensitive and non-specific observation of outcomes in time-to-event data affects event counts 
as well as the risk sets, thus, biasing the estimation of hazard ratios. We investigate how imperfect observation of 
incident events affects the estimation of vaccine effectiveness based on hazard ratios.
Methods: Imperfect time-to-event data contain two classes of events: a portion of the true events of interest; and 
false-positive events mistakenly recorded as events of interest. We develop an estimation method utilising a weighted 
partial likelihood and probabilistic deletion of false-positive events and assuming the sensitivity and the false-positive 
rate are known. The performance of the method is evaluated using simulated and Finnish register data.
Results: The novel method enables unbiased semiparametric estimation of hazard ratios from imperfect time-to-
event data. False-positive rates that are small can be approximated to be zero without inducing bias. The method is 
robust to misspecification of the sensitivity as long as the ratio of the sensitivity in the vaccinated and the unvacci-
nated is specified correctly and the cumulative risk of the true event is small.
Conclusions: The weighted partial likelihood can be used to adjust for outcome measurement errors in the estima-
tion of hazard ratios and effectiveness but requires specifying the sensitivity and the false-positive rate. In absence of 
exact information about these parameters, the method works as a tool for assessing the potential magnitude of bias 
given a range of likely parameter values.
Keywords: Influenza, Outcome measurement error, Proportional hazards model, Survival analysis, Vaccine 
effectiveness
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Introduction
Outcome measurement errors are common in epide-
miological studies and may bias the estimated effects of 
exposures or interventions on health outcomes. When 
a binary outcome such as presence/absence of infection 
is measured with error, the problem is called outcome 
misclassification [1]. The impact of outcome misclas-
sification on estimation of risk ratios has been studied 
thoroughly [2–4]. Nevertheless, the same lessons cannot 
be readily adopted when estimating hazard ratios from 
time-to-event data because imperfectly observed event 
times do not only affect event counts but may also bias 
the at-risk times and thus the risk set sizes.
A particular problem arises when estimating vac-
cine effectiveness as the relative reduction in the infec-
tion hazard. If infection-induced immunity reduces 
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same pathogen, non-sensitive measurement of infec-
tion inflates the risk set. For example, influenza is likely 
to immunise the human host at least temporarily and 
all infections in a large population are never recorded in 
practice. Moreover, false-positive records may occur due 
to imperfect specificity of diagnostic procedures.
Yang et  al. [5] addressed estimation of vaccine effec-
tiveness under non-specific observation of influenza 
infection using a subset of acute respiratory infections 
as a validation set on disease aetiology. An expecta-
tion–maximisation algorithm was developed to account 
for the uncertainty in the aetiology of infections outside 
the validation set [5]. Although the validation data car-
ried information on the specificity, perfect sensitivity was 
assumed.
Meier et  al. [6] focused on detection of chronic out-
comes such as human immunodeficiency virus infection, 
which if initially missed can still be detected by later test-
ing. A full-likelihood approach was developed to estimate 
the hazard ratio under repeated usage of an imperfect 
laboratory test, based on a proportional hazards (PH) 
model in discrete time and assuming the test sensitivity 
and specificity are known [6]. However, this method can-
not be applied under imperfect observation of incident 
events, such as influenza infection, which by standard 
laboratory tests can only be detected up to one week after 
symptom onset [7].
The role of non-sensitive and non-specific observation 
of incident infection outcomes on the estimation of haz-
ard ratios has thus not been fully covered in previous lit-
erature. We here study how outcome measurement errors 
affect the estimation of vaccine effectiveness based on 
hazard ratios. We modify the standard partial likelihood 
under the PH model [8] to adjust for outcome measure-
ment errors in time-to-event data, assuming the sensitiv-
ity and the false-positive rate are known. We explore the 
magnitude of bias when the measurement errors are not 
corrected for and evaluate the robustness of effectiveness 
estimates to misspecification of the sensitivity and the 
false-positive rate. We implement the new method in R 
[9] (see Additional file 1: R script) and use simulated and 
Finnish register data to show its performance. Our work 
is motivated by the Finnish policy of estimating influenza 
vaccine effectiveness each season from register data [10], 
which do not include influenza-negative test results and 
thus do not allow for a retrospective design such as the 
widely used test-negative design [11]. Therefore, we here 
focus exclusively on cohort studies.
Methods
True and false‑positive events
We consider the sensitivity of outcome measurement as 
the conditional probability for the true event of interest 
being recorded in the data. When the sensitivity is less 
than 1, some true events may not be recorded. Addition-
ally, other events may be mistakenly recorded as events of 
interest. Such false-positive records make outcome meas-
urement non-specific. Here, the true event means influ-
enza infection while false-positive events are any other 
(non-influenza) events incorrectly recorded as influenza.
For any one subject, let the hazard of the true event 
at time t be (t) . We assume that the true event occurs 
at most once during the study period, and if it occurs, is 
recorded with sensitivity se . False-positive events may 
occur repeatedly at rate κ(t) . Originally, the data may 
thus comprise more than one event per subject. In the 
study, however, based on the assumption that the true 
event is unique, each subject’s follow-up is set to end 
at his/her first recorded event or censoring, whichever 
occurs first. The data under study therefore comprise at 
most one recorded event per subject (Fig. 1). The event’s 
status as true or false positive is indistinguishable by 
observation.
If the true event occurs but is not recorded, the sub-
ject’s follow-up continues beyond the true event time, 
Fig. 1 Occurrence of true and false-positive influenza events. The 
figure shows the eight possible paths of events for a study subject 
during the study period (influenza season). The true event is depicted 
either by a white circle if it was recorded or by a crossed circle if it 
was not recorded. False-positive events are depicted by black circles. 
Although false positives may occur repeatedly, the figure shows only 
the first of these if any. The subject’s true time at risk during the study 
period is marked by a solid line. In the study, the subject’s follow-up 
(dashed line) ends at the time of the first recorded event, which is 
highlighted by a square around the event-defining circle, or at the 
time of censoring (vertical bar). Although recorded, the true event is 
not part of the data under study if there is a preceding false-positive 
event. The true at-risk time is then underestimated (Paths 2, 5 and 8). 
By contrast, Paths 6 and 7 show scenarios in which the true at-risk 
time is overestimated
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erroneously lengthening the at-risk time in the study. By 
contrast, should a false-positive event occur before the 
true event, the subject’s follow-up ends prematurely and 
the true event time is not part of the data under study 
(Fig.  1). This also shows that minor violations of the 
above assumption of uniqueness would not compromise 
the study.
True and observed survival functions
The true survival function S(t) is the probability to escape 
the true event beyond time t . The observed survival func-
tion S̃(t) is the probability to avoid detection of the true 
event and the occurrence of any false-positive events 
beyond t . Assuming constant sensitivity ( se ) and false-
positive rate ( κ ), the relationship between the survival 
functions is (cf. Additional file 2: Web Appendix)
The first right-hand-side term is the complement 
probability of the true event having occurred and been 
recorded by t . The second term is the probability of no 
false-positive events having occurred by t.
True and observed hazards
Given expression (1), the relation between the hazard ̃(t) 
of the recorded event (observed hazard) and the hazard 
(t) of the true event (true hazard) follows (cf. Additional 
file 2: Web Appendix):
 where the weight w(t) is defined as
The observed hazard is thus the sum of the hazard of 
recording the true event and the false-positive rate. The 
sensitivity se accounts for the possibility of not record-
ing the true event. The weight w(t) equals the ratio of 
the true survival probability and the survival probability 
observed in absence of false positives and adjusts for the 
fact that a true but unrecorded event may have already 
removed the subject from the study’s risk set before time 
t . It holds that w(t) ≤ 1.
(1)S̃(t; se, κ) = [1− se · (1− S(t))] · e(−κt).
(2)
̃(t; se, κ) = se ·
S(t)
S̃(t; se, κ = 0)
· (t)+ κ
= se · w(t) · (t)+ κ ,
w(t) =
S(t)
S̃(t; se, κ = 0)
.
Vaccine effectiveness
We compare the true hazards between two groups 
defined by vaccination as binary exposure. Specifically, 
0(t) and 1(t) denote the true hazards for unvaccinated 
and vaccinated subjects, respectively, as functions of 
time since season onset. The estimand of interest is 
vaccine effectiveness ( VE ) defined as the relative reduc-
tion in the infection hazard [12]:
In this paper, the true hazards in unvaccinated and 
vaccinated subjects are assumed to be proportional 
over time so that the VE estimand is constant. If κ = 0 , 
it follows from (2) that
where
and v = 0 (unvaccinated) or 1 (vaccinated).
Weighted partial likelihood under imperfect sensitivity 
in absence of false positives
The data under study comprise n recorded events in a 
cohort of unvaccinated and vaccinated subjects. The 
event times of the n cases are t1 < t2 < · · · < tn . Let 
Ñ0(ti) and Ñ1(ti) denote the numbers of unvaccinated 
and vaccinated subjects in the risk set at ti . Of note, a 
subject’s vaccination status may change over time [10].
Under the PH assumption, the hazard ratio and 
thus VE can be estimated from complete and perfectly 
measured time-to-event data by maximising the stand-
ard partial likelihood [8]. Here, we adjust the partial 
likelihood to allow estimation of VE under imperfect 
sensitivity. When se0 and se1 are known, the partial like-
lihood of VE is. 
 where Li(VE) is the conditional probability for the event 
occurring to case i given the risk set at ti , and vi is 0 if 






(3)̃v(t; se, κ = 0) = (1− VE)v · sev · wv(t) · 0(t),
wv(t) =
Sv(t)


















(1− VE)vi · sevi · wvi(ti)
se0 · w0(ti) · Ñ0(ti)+ (1− VE) · se1 · w1(ti) · Ñ1(ti)
, i = 1, . . . , n.
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Unlike the standard partial likelihood, (5) depends on 
weights w0(t) and w1(t) , which correct for the too large risk 
set following from imperfect sensitivity. Using the Kaplan–
Meier estimate ̂̃S(t) for S̃(t; se, κ = 0) leads to plug-in 
weights ŵ0(t) and ŵ1(t) (cf. Additional file 2: Web Appendix): 
VE is estimated by maximising (4) and its standard 
error ( SE ) can be obtained using the Fisher informa-
tion. If se0 = se1 = 1 , (4) simplifies to the standard par-
tial likelihood.
Probabilistic deletion of false‑positive events
If false-positive events occur, i.e. if κ > 0 , semipara-
metric estimation using the weighted partial likelihood 
is not directly applicable as the true hazard 0(t) does 
not cancel out affecting expression (5). We propose an 
approach that retains only a portion of the n recorded 
events by approximating the time-varying probability 
of the recorded event being a true event.
The probability that an event observed at time ti is a 
true event is given by the ratio of the hazard of record-
ing the true event to the observed hazard. This prob-
ability is (cf. Additional file 2: Web Appendix)
We suggest approximating ̃v(ti) over a short time 
window ( ti ) centred around ti as the number of 
events observed ( D̃v,i ) per person-time ( Ñv(ti) ·�ti ) 
and, hence, an approximation to pv(ti) is given by
Subsequently, any event observed at ti is retained 
in the data with probability pv(ti) , corresponding to 
censoring events at each ti with probability 1− pv(ti) . 
In analogy to multiple imputation, the above proce-
dure is repeated a number of times to produce repli-
cate data sets. Each resulting set of time-to-event data 
is analysed as in absence of false positives using the 
weighted partial likelihood. At the end, the VE esti-
mates are pooled taking into account the within- and 
the between-imputation variability [13].
Simulation study
Set‑up
We conducted a simulation study to assess the perfor-














were simulated according to hazards 0(t) (unvaccinated) 
and (1− VE) · 0(t) (vaccinated), where 0(t) mimicked 
the force of infection in a Susceptible-Infected-Removed 
epidemic [14] with cumulative risk of 0.25 (alternatively 
0.81) over a 196-day influenza season (cf. Additional file 2: 
Web Appendix). Two separate cohorts were considered, 
comprising 50,000 (30% vaccinated at season onset) and 
1,000,000 (50% vaccinated) individuals, corresponding to 
the cohort sizes of Finnish children and elderly, respec-
tively [10, 15, 16]. VE was 10%, 30%, 50%, 70% or 90%.
For each individual, observed true events were real-
ised by retaining simulated true events with sensi-
tivities se0 (unvaccinated) and se1 (vaccinated). Values 
se0 = se1 = 0.04 were based on a Finnish study of the 
2009/10 influenza season [17]. Alternatively, values 
se0 = 0.05 and se1 = 0.03 were employed to investigate 
differential sensitivity. A false-positive event time was 
sampled from the exponential distribution with rates 
corresponding to 2% or 16% of all recorded events in 
the unvaccinated being false-positive. The smaller of the 
observed true and false-positive event times was used as 
the recorded event time for the individual.
For each setting (cohort size, VE , se0 , se1 and κ ),  104 
repeated datasets were simulated. For each dataset, 
ten random subsets were created by retaining events 
with probability p(t) as in (8). Adjusted VE estimates 
were computed with the same values of se0 , se1 and κ as 
used in simulation. In addition, naïve VE estimates were 
obtained by incorrectly assuming perfect sensitivity 
( se0 = se1 = 1 ) and/or absence of false positives ( κ = 0 ). 
Finally, the ten dataset-specific estimates were pooled 
resulting in  104 estimates of VE and SE per setting.
We report the bias as the difference between the mean 
of VE estimates ( ̂VE ) and the true VE . We compare the 
mean of the SE estimates ( ̂SE ) with the empirical stand-
ard error of the VE estimates ( SE
V̂E





 ) is assessed as the root-mean-squared error 
between the VE estimates and the true VE . The empirical 
coverage probability of the 95% confidence interval (CI) 
was estimated as the percentage of  104 CIs that included 
the true VE.
Estimation of vaccine effectiveness under imperfect 
sensitivity in absence of false‑positive events
Tables 1 and 2 show the adjusted and naïve VE estimates 
under non-differential sensitivity ( se0 = se1 = 0.04 ) and 
differential sensitivity  (se0 = 0.05 , se1 = 0.03 ), respec-
tively, with κ = 0 and cumulative risk of 0.25 in the 
unvaccinated. Table 3 and Additional file 2: Table S1 (see 
Additional file 2: Web Appendix) show the correspond-
ing estimates under cumulative risk of 0.81.  
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The adjusted V̂E ’s are unbiased. Therefore, the 







 ). Because the uncertainty in the plug-
in weights is not taken into account, the standard errors 
are slightly underestimated ( ̂SE < SE
V̂E
 ), leading to 
smaller than nominal CI coverage probabilities.
Under non-differential sensitivity, the naïve V̂E ’s 
underestimate the true VE . The bias is stronger when 
the cumulative risk is high (0.81). When the cumula-
tive risk is small (0.25), the estimation errors in the 
naïve and adjusted estimates are similar. However, as 
standard errors may be small, even slight biases can 
lead to poor CI coverage. Under differential sensitivity 
Table 1 Estimates of vaccine effectiveness ( VE ) under non-differentially imperfect sensitivity and small cumulative risk 
of infection in absence of false-positive events
Mean of the vaccine effectiveness estimates ( ̂VE ), mean of the standard error estimates ( ŜE ), standard error of the vaccine effectiveness estimates ( SE
V̂E
 ), root-




 ), bias in percentage points, and empirical coverage probability (Cov) of the 95% confidence 
intervals when estimating vaccine effectiveness from  104 repeated data sets under non-differential sensitivity ( se0 = se1 ) of 0.04 and a cumulative risk of 0.25 in the 
unvaccinated in absence of false-positive events. Naïve estimation was conducted under the incorrect assumption of perfect sensitivity ( se0 = se1 = 1)
True Estimation adjusted for se0 = se1 = 0.04 Naïve estimation









Cohort of 50,000 individuals (30% vaccinated at season onset)
 10% 10% 0.09 0.10 0.10  ± 0 92% 9% 0.09 0.09 0.09 − 1 95%
 30% 30% 0.08 0.09 0.09  ± 0 92% 27% 0.08 0.08 0.09 − 3 95%
 50% 50% 0.06 0.07 0.07  ± 0 93% 46% 0.07 0.07 0.08 − 4 94%
 70% 70% 0.05 0.05 0.05  ± 0 93% 67% 0.05 0.05 0.06 − 3 93%
 90% 90% 0.02 0.03 0.03  ± 0 94% 89% 0.03 0.03 0.03 − 1 95%
Cohort of 1,000,000 individuals (50% vaccinated at season onset)
 10% 10% 0.02 0.02 0.02  ± 0 92% 9% 0.02 0.02 0.02 − 1 91%
 30% 30% 0.02 0.02 0.02  ± 0 91% 27% 0.02 0.02 0.03 − 3 57%
 50% 50% 0.01 0.01 0.01  ± 0 93% 47% 0.01 0.01 0.04 − 3 23%
 70% 70% 0.01 0.01 0.01  ± 0 94% 67% 0.01 0.01 0.03 − 3 10%
 90% 90% 0.00 0.00 0.00  ± 0 94% 89% 0.01 0.01 0.01 − 1 26%
Table 2 Estimates of  vaccine effectiveness ( VE ) under  differential sensitivity and  small cumulative risk of  infection 
in absence of false-positive events
Mean of the vaccine effectiveness estimates ( ̂VE ), mean of the standard error estimates ( ŜE ), standard error of the vaccine effectiveness estimates ( SE
V̂E
 ), root-mean-




 ), bias in percentage points, and empirical coverage probability (Cov) of the 95% confidence intervals 
when estimating vaccine effectiveness from  104 repeated data sets under differential sensitivity of 0.05 ( se0 ) and 0.03 ( se1 ) and a cumulative risk of 0.25 in the 
unvaccinated in absence of false-positive events. Naïve estimation was conducted under the incorrect assumption of perfect sensitivity ( se0 = se1 = 1)
True Estimation adjusted for se0 = 0.05, se1 = 0.03 Naïve estimation









Cohort of 50,000 individuals (30% vaccinated at season onset)
 10% 10% 0.10 0.11 0.11  ± 0 91% 45% 0.06 0.06 0.36  + 35 0%
 30% 30% 0.08 0.09 0.09  ± 0 92% 56% 0.05 0.05 0.27  + 26 1%
 50% 50% 0.07 0.08 0.08  ± 0 92% 68% 0.04 0.04 0.19  + 18 4%
 70% 70% 0.05 0.05 0.05  ± 0 93% 80% 0.03 0.03 0.11  + 10 19%
 90% 90% 0.03 0.03 0.03  ± 0 93% 93% 0.02 0.02 0.04  + 3 57%
Cohort of 1,000,000 individuals (50% vaccinated at season onset)
 10% 10% 0.02 0.02 0.02  ± 0 92% 45% 0.01 0.01 0.35  + 35 0%
 30% 30% 0.02 0.02 0.02  ± 0 91% 56% 0.01 0.01 0.26  + 26 0%
 50% 50% 0.01 0.01 0.01  ± 0 93% 68% 0.01 0.01 0.18  + 18 0%
 70% 70% 0.01 0.01 0.01  ± 0 94% 80% 0.01 0.01 0.10  + 10 0%
 90% 90% 0.01 0.01 0.01  ± 0 94% 93% 0.00 0.00 0.03  + 3 0%
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( se0 > se1 ) and small cumulative risk, the naïve V̂E ’s 
overestimate the true VE . The estimation error in the 
naïve estimates exceeds the one in the adjusted esti-
mates indicating that the estimation is not robust to 
gross misspecification of se0 and se1 . The error attenu-
ates when the cumulative risk is high.
Estimation of vaccine effectiveness under imperfect 
sensitivity and false‑positive events
Table  4 and Additional file  2: Table  S2 (see Addi-
tional file  2: Web Appendix) show the adjusted 
and naïve VE estimates under non-differential sen-
sitivity ( se0 = se1 = 0.04 ) and differential sensi-
tivity  (se0 = 0.05 , se1 = 0.03 ), respectively, with 
cumulative risk of 0.25 and false-positive proportion 
of 2% among unvaccinated. In general, the results cor-
respond to the situation without false positives. The 
adjusted V̂E ’s are essentially unbiased. As the naïve 
V̂E ’s do not differ much between settings with and 
without false positives, a false-positive rate corre-
sponding to a false-positive proportion of 2% among 
unvaccinated does not essentially affect the estima-
tion. However, under the higher false-positive pro-
portion (16%) naïve estimates are biased but adjusted 
estimation performs well (Table 5). 
Influenza vaccine effectiveness in the Finnish elderly
This section presents estimates of influenza vaccine 
effectiveness in Finnish elderly in 2016/17, a season 
dominated by influenza subtype A/H3N2. Briefly, a 
nationwide cohort of individuals aged 65  years and 
above was monitored through the season (196  days), 
using data collected as part of healthcare routines. The 
outcome was laboratory-confirmed influenza, which is 
a non-sensitive measurement of influenza infection as 
not everyone seeks healthcare or is swabbed. The reg-
ister-based cohort study design is described in detail 
elsewhere [10]. For simplicity, we here focus on out-
come measurement errors assuming absence of other 
sources of bias such as exposure measurement errors or 
confounding.
The cohort totalled 1,160,986 individuals of which 
47% were vaccinated during the season. There were 8389 
recorded events of which 3346 occurred in vaccinated 
individuals. Unlike in the simulation study, VE , se0 , se1 
and κ were unknown. The sensitivities ( se0 , se1 ) were set 
at 0.04 (cf. Shubin et al. [17]). The false-positive rate ( κ ) 
was deemed very small and thus approximated as 0.
The estimated cumulative risks over the season were 
0.20 (unvaccinated) and 0.16 (vaccinated; Fig.  2a). The 
linear relation between the log–log transformed survival 
functions supports the PH assumption (Fig.  2b). The 
adjusted VE estimate at t = 196 (days) was 23% (95% CI 
20–26%; Fig. 2c) similar to the naïve ( se0 = se1 = 1 ) esti-
mate 21% (95% CI 17–24%; Fig. 2d).
The estimates were mainly affected by the ratio se1/se0 
unless se0 was chosen very small (Fig.  2d). Assuming 
se0 = se1 = 0.01 , for instance, implied rather unreal-
istic cumulative risks of 0.81 (unvaccinated) and 0.64 
(vaccinated). The corresponding VE estimate was 37% 
(95% CI 34%–39%). If vaccinated cases were assumed 
Table 3 Estimates of  vaccine effectiveness ( VE ) under  non-differentially imperfect sensitivity and  high cumulative risk 
of infection in absence of false-positive events
Mean of the vaccine effectiveness estimates ( ̂VE ), mean of the standard error estimates ( ŜE ), standard error of the vaccine effectiveness estimates ( SE
V̂E
 ), root-




 ), bias in percentage points, and empirical coverage probability (Cov) of the 95% confidence 
intervals when estimating vaccine effectiveness from  104 repeated data sets under non-differential sensitivity ( se0 = se1 ) of 0.04 and a cumulative risk of 0.81 in the 
unvaccinated in absence of false-positive events. Naïve estimation was conducted under the incorrect assumption of perfect sensitivity ( se0 = se1 = 1)
True Estimation adjusted for se0 = se1 = 0.04 Naïve estimation









Cohort of 50,000 individuals (30% vaccinated at season onset)
 10% 10% 0.05 0.10 0.10  ± 0 67% 4% 0.05 0.05 0.08 − 6 82%
 30% 30% 0.04 0.08 0.08  ± 0 70% 15% 0.05 0.05 0.16 − 15 11%
 50% 50% 0.03 0.05 0.05  ± 0 75% 30% 0.04 0.04 0.20 − 20 0%
 70% 70% 0.02 0.03 0.03  ± 0 80% 51% 0.03 0.03 0.19 − 19 0%
 90% 90% 0.01 0.01 0.01  ± 0 88% 81% 0.02 0.02 0.09 − 9 0%
Cohort of 1,000,000 individuals (50% vaccinated at season onset)
 10% 10% 0.01 0.02 0.02  ± 0 66% 4% 0.01 0.01 0.06 − 6 0%
 30% 30% 0.01 0.02 0.02  ± 0 69% 15% 0.01 0.01 0.15 − 15 0%
 50% 50% 0.01 0.01 0.01  ± 0 71% 30% 0.01 0.01 0.20 − 20 0%
 70% 70% 0.00 0.01 0.01  ± 0 75% 52% 0.01 0.01 0.18 − 18 0%
 90% 90% 0.00 0.00 0.00  ± 0 83% 81% 0.00 0.00 0.09 − 9 0%
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to be less likely detected ( se1/se0 < 1 ), the VE estimates 
were smaller than 23%, and vice versa. For example, if 
se1 = 0.04 and se0 = 0.05 , VE was 2% with 95% CI from 
–3% to 6%, indicating that vaccination may not have 
been effective.
Discussion
Motivated by the Finnish policy of evaluating influ-
enza vaccine effectiveness from register data, we devel-
oped a weighted partial likelihood approach with 
probabilistic deletion of false positives to adjust for 
Table 4 Estimates of  vaccine effectiveness ( VE ) under  non-differentially imperfect sensitivity, small cumulative risk 
of infection and low rate of false-positive events
Mean of the vaccine effectiveness estimates ( ̂VE ), mean of the standard error estimates ( ŜE ), standard error of the vaccine effectiveness estimates ( SE
V̂E
 ), root-




 ), bias in percentage points, and empirical coverage probability (Cov) of the 95% confidence 
intervals when estimating vaccine effectiveness from  104 repeated data sets given non-differential sensitivity ( se0 = se1 ) of 0.04 and a cumulative risk of 0.25 in the 
unvaccinated. The false-positive events occurred at rate κ = 10−6 (per person-day) corresponding to a false-positive proportion of 2% among the unvaccinated. Naïve 
estimation was conducted under the incorrect assumptions of perfect sensitivity ( se0 = se1 = 1 ) and absence of false positives ( κ = 0)
True Estimation adjusted for se0 = se1 = 0.04, κ = 10−6 Naïve estimation









Cohort of 50,000 individuals (30% vaccinated at season onset)
 10% 10% 0.09 0.11 0.11  ± 0 92% 8% 0.09 0.09 0.09 − 2 95%
 30% 30% 0.08 0.09 0.09  ± 0 92% 26% 0.08 0.08 0.09 − 4 95%
 50% 50% 0.06 0.07 0.07  ± 0 93% 46% 0.07 0.07 0.08 − 4 93%
 70% 69% 0.05 0.05 0.05 − 1 94% 66% 0.05 0.05 0.07 − 4 90%
 90% 89% 0.03 0.03 0.03 − 1 96% 87% 0.03 0.03 0.04 − 3 88%
Cohort of 1,000,000 individuals (50% vaccinated at season onset)
 10% 10% 0.02 0.02 0.02  ± 0 92% 9% 0.02 0.02 0.02 − 1 89%
 30% 30% 0.02 0.02 0.02  ± 0 91% 27% 0.02 0.02 0.04 − 3 44%
 50% 50% 0.01 0.01 0.01  ± 0 93% 46% 0.01 0.01 0.05 − 4 7%
 70% 70% 0.01 0.01 0.01  ± 0 94% 66% 0.01 0.01 0.04 − 4 0%
 90% 90% 0.00 0.00 0.00  ± 0 94% 87% 0.01 0.01 0.03 − 3 0%
Table 5 Estimates of  vaccine effectiveness ( VE ) under  non-differentially imperfect sensitivity, small cumulative risk 
of infection and high rate of false-positive events
Mean of the vaccine effectiveness estimates ( ̂VE ), mean of the standard error estimates ( ŜE ), standard error of the vaccine effectiveness estimates ( SE
V̂E
 ), root-




 ), bias in percentage points, and empirical coverage probability (Cov) of the 95% confidence 
intervals when estimating vaccine effectiveness from  104 repeated data sets given non-differential sensitivity ( se0 = se1 ) of 0.04 and a cumulative risk of 0.25 in the 
unvaccinated. The false-positive events occurred at rate κ = 10−5 (per person-day) corresponding to a false-positive proportion of 16% among the unvaccinated. 
Naïve estimation was conducted under the incorrect assumptions of perfect sensitivity ( se0 = se1 = 1 ) and absence of false positives ( κ = 0)
True Estimation adjusted for se0 = se1 = 0.04, κ = 10−5 Naïve estimation









Cohort of 50,000 individuals (30% vaccinated at season onset)
 10% 9% 0.10 0.11 0.12 − 1 92% 7% 0.09 0.09 0.09 − 3 95%
 30% 29% 0.09 0.10 0.10 − 1 92% 23% 0.08 0.08 0.11 − 7 87%
 50% 49% 0.07 0.08 0.08 − 1 93% 39% 0.07 0.07 0.13 − 11 63%
 70% 68% 0.05 0.06 0.06 − 2 93% 56% 0.05 0.05 0.15 − 14 23%
 90% 86% 0.04 0.04 0.05 − 4 85% 74% 0.04 0.04 0.17 − 16 0%
Cohort of 1,000,000 individuals (50% vaccinated at season onset)
 10% 10% 0.02 0.02 0.02  ± 0 92% 7% 0.02 0.02 0.03 − 3 67%
 30% 30% 0.02 0.02 0.02  ± 0 91% 23% 0.02 0.02 0.07 − 7 0%
 50% 50% 0.01 0.01 0.01  ± 0 92% 39% 0.01 0.01 0.11 − 11 0%
 70% 70% 0.01 0.01 0.01  ± 0 92% 56% 0.01 0.01 0.14 − 14 0%
 90% 90% 0.01 0.01 0.01  ± 0 87% 74% 0.01 0.01 0.16 − 16 0%
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outcome measurement errors. A simulation study dem-
onstrated that the new method enables unbiased esti-
mation of hazard ratios from time-to-event data when 
the underlying sensitivity of outcome measurement and 
the false-positive rate are known. In practise, false-pos-
itive rates that are small in relation to the true hazard 
can be approximated to be zero without inducing bias. 
Moreover, the analysis of empirical data showed that the 
method is robust to misspecification of the sensitivity 
parameters as long as their ratio ( se1/se0 ) is set correctly 
and the cumulative risk of the true event is small.
We assumed the influenza vaccine’s mode of action is 
“leaky”, i.e. that vaccination provides only partial pro-
tection [12, 18, 19]. The appropriate effect measure of 
effectiveness is therefore the relative reduction in the 
infection hazard, assumed here to be constant over one 
influenza season. When estimating effectiveness based 
on the risk ratio, it has previously been shown that bias 
is determined by the ratio of the two sensitivity param-
eters [4]. We demonstrated that the same applies when 
effectiveness is based on the hazard ratio but only if the 
cumulative risk of the outcome is small, i.e. if the out-
come is rare so that the risk set is largely unaffected by 
the occurrence of events.
Unlike in studies that exclusively refer to sensitivity as 
performance of a utilised laboratory test (e.g. [2]), regis-
ter-based studies (e.g. [20]) use sensitivity in a broader 
sense as resulting from recording accuracy, healthcare 
Fig. 2 Estimates of influenza vaccine effectiveness in the Finnish elderly (N = 1,160,986) in 2016/17. A: Kaplan–Meier estimates of the observed 
survival functions in the unvaccinated ( ̂̃S0(t) ) and vaccinated ( ̂̃S1(t) ) and the corresponding estimates of the true survival functions ( ̂S0(t) , Ŝ1(t) ) 
based on (1) assuming non-differential sensitivity ( se0 , se1 ) of 0.04 and absence of false-positive events. The estimated cumulative risks ( 1− Ŝ0(t) , 
1− Ŝ1(t) ) at t = 196 (days) were 0.20 and 0.16. B: The linear relation between the log–log transformed survival functions Ŝ0(t) and Ŝ1(t) supports 
the proportional hazards assumption (cf. Additional file 2: Web Appendix). C: Time evolution of vaccine effectiveness estimates (solid line) and 
pointwise 95% confidence intervals (dashed lines) based on (4). D: Dependence of vaccine effectiveness estimates at t = 196 (days) on the assumed 
values of se0 (symbols) and ratio se1/se0 (horizontal axis) based on (4). The plot area has been restricted showing only non-negative vaccine 
effectiveness estimates. For the full range see Additional file 2: Figure S1 (see Additional file 2: Web Appendix)
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seeking behaviour, swabbing policy and the sensitivity of 
diagnostic procedures. Based on a priori knowledge on 
surveillance practice in Finland and register data on lab-
oratory-confirmed influenza, Shubin et al. [17] estimated 
that only 1 in 25 infections were ascertained and that 
the sensitivity varied across age, region and season. We 
expect that there are also differences by vaccination sta-
tus but well-founded values for the sensitivity parameters 
se0 and se1 are not yet available. A study that closely fol-
lows a representative sample of the population through 
an influenza season and continuously validates the indi-
viduals’ infection status would be needed.
False-positive events result from diagnostic proce-
dures with imperfect specificity. In register-based stud-
ies, the false-positive rate is additionally influenced by 
the accuracy of recording, sampling strategy, the rate of 
non-influenza but influenza-like illness, and healthcare 
seeking behaviour. Although the new method allows 
accounting for time-varying and differential occurrence 
of false positives (cf. Additional file  2: Web Appendix), 
the presented simulation study used constant false-pos-
itive rates corresponding to 2% or 16% of all recorded 
events in the unvaccinated being false-positive.
The simulation study results show that the impact of 
relatively small false-positive rates is negligible. Yang 
et  al. [5] developed an expectation–maximisation algo-
rithm to estimate VE under non-specific observation of 
incident events when all true events are observed and 
validation data are available. Similarly to our method, 
their approach employs empirical hazards to address 
the problem of false positives. While Yang et  al. allow 
repeated events, in our application the at-risk time is cen-
sored at the first recorded event. The data might then run 
short of true events if the false-positive rate is excessively 
high.
Conclusion
The presented semiparametric method can be used 
to adjust for outcome measurement errors in the esti-
mation of hazard ratios and effectiveness but requires 
specifying the sensitivity and the false-positive rate. In 
absence of exact information about these parameters, 
we consider our method as a tool for assessing the 
potential magnitude of bias given a range of parameter 
values, possibly stratified by appropriate covariates. The 
method would allow adjustment for confounders as in 
the PH model. Finally, although we considered an infec-
tious disease epidemic, the applicability of the method 
is wider as long as the PH assumption holds.
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